Abstract
PET imaging of cannabinoid type 1 receptor (CB1) is important for assessment of the receptor role in many neurological and psychiatric disorders. 5-(4-(2-[18F]fluoroethoxy)phenyl)-1-(2,4-dichlorophenyl)-4-cyano-N-(piperidin-1- yl)-1H-pyrazole-3-carboxamide ([18F]JHU88868), an analog of the radiotracer of choice for PET imaging of CB1 receptors in humans [11C]JHU75528 ([11C]OMAR), with a longer half-life exhibits high CB1 binding affinity (Ki = 16, 17 nM) and moderate lipophilicity. An efficient synthesis of JHU88868 and its bromoethoxy derivative for radiolabeling are presented. [18F]-2 ([18F]JHU88868) was prepared in one step by a Kryptofix-assisted radiofluorination of the corresponding bromo-precursor in DMSO solution at 135°C using a nucleophilic fluorination radiochemistry box with radiochemical yield of 1-5 %, radiochemical purity greater than 95% and the average specific activity of 4000 mCi/μmol at the end-ofsynthesis.
Keywords: Cannabinoid receptor, positron emission tomography (PET), radiofluorination
Current Radiopharmaceuticals
Title: 5-(4-(2-[ F]fluoroethoxy)phenyl)-1-(2,4-dichlorophenyl)-4-cyano-N- (piperidin-1-yl)-1H-pyrazole-3-carboxamide ([ F]JHU88868), a Novel Radioligand for PET Imaging of Cannabinoid Type 1 Receptors
Volume: 2 Issue: 3
Author(s): Yongjun Gao, Hayden T. Ravert, Robert F. Dannals and Andrew G. Horti
Affiliation:
Keywords: Cannabinoid receptor, positron emission tomography (PET), radiofluorination
Abstract: PET imaging of cannabinoid type 1 receptor (CB1) is important for assessment of the receptor role in many neurological and psychiatric disorders. 5-(4-(2-[18F]fluoroethoxy)phenyl)-1-(2,4-dichlorophenyl)-4-cyano-N-(piperidin-1- yl)-1H-pyrazole-3-carboxamide ([18F]JHU88868), an analog of the radiotracer of choice for PET imaging of CB1 receptors in humans [11C]JHU75528 ([11C]OMAR), with a longer half-life exhibits high CB1 binding affinity (Ki = 16, 17 nM) and moderate lipophilicity. An efficient synthesis of JHU88868 and its bromoethoxy derivative for radiolabeling are presented. [18F]-2 ([18F]JHU88868) was prepared in one step by a Kryptofix-assisted radiofluorination of the corresponding bromo-precursor in DMSO solution at 135°C using a nucleophilic fluorination radiochemistry box with radiochemical yield of 1-5 %, radiochemical purity greater than 95% and the average specific activity of 4000 mCi/μmol at the end-ofsynthesis.
Export Options
About this article
Cite this article as:
Gao Yongjun, Ravert T. Hayden, Dannals F. Robert and Horti G. Andrew, 5-(4-(2-[ F]fluoroethoxy)phenyl)-1-(2,4-dichlorophenyl)-4-cyano-N- (piperidin-1-yl)-1H-pyrazole-3-carboxamide ([ F]JHU88868), a Novel Radioligand for PET Imaging of Cannabinoid Type 1 Receptors, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030195
DOI https://dx.doi.org/10.2174/1874471010902030195 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets
CNS & Neurological Disorders - Drug Targets Oral Disintegrating Tablets – An Updated Patent Perspective
Recent Patents on Drug Delivery & Formulation Meet Our Editorial Board Member
Current Alzheimer Research Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Severe Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research
Current Neurovascular Research Editorial: Risks and Opportunities in Adolescence
Adolescent Psychiatry A Spectrum of Topics for 2019: Advances in Neuroinflammation, Oxidative Stress, Obesity, Diabetes Mellitus, Cardiovascular Disease, Autism, Exosomes, and Central Nervous System Diseases
Current Pharmaceutical Design Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Impact of Religious Retreats on Disruptive Behaviors in Incarcerated Youth
Adolescent Psychiatry Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Pivotal Role of the Interaction Between Herbal Medicines and Gut Microbiota on Disease Treatment
Current Drug Targets Retinal Imaging: A New Tool for Studying Underlying Liability to Cardiovascular Disease in Schizophrenia
Current Psychiatry Reviews Role of Infection Control in Prevention of Hepatitis B virus (HBV) in Hemodialysis (HD) Patients.
Infectious Disorders - Drug Targets An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Strategies to Treat Substance Abuse and Addiction (Guest Editor: Christopher R. McCurdy)]
Current Topics in Medicinal Chemistry Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology